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CHAPTER I. GENERAL INTRODUCTION 
Introduction 
Colorectal cancer has a high death rate among cancer related diseases in the United 
States. An inverse relationship between fruit and vegetable consumption and colon cancer 
risk has been observed in several epidemiological studies (Steinmetz and Potter, 1991). 
Vitamins, phytochemicals and dietary fibers which are rich in fruit and vegetables are 
believed to have cancer preventive effects (Potter and Steinmetz, 1996) . 
Resveratrol, 3, 5, 4'-trihydroxystilbene, is a biologically active constituent in grapes, 
red wine and plants such as peanuts, eucalyptus, spruce, lily and mulberries. The 
chemopreventive effects of resveratrol in colon cancer have been studied both in vivo and in 
vitro. In animal models, resveratrol was found to inhibit azoxymethane (AOM) induced 
aberrant crypt foci (ACF) and also reduce the formation of small intestine tumors in Min 
mice, which have a genetic mutation in the adenomatous polyposis coli (APC) gene. 
Resveratrol was also found to inhibit cell growth, induce cell cycle arrest and apoptosis in 
various colon cancer cells. Studies showed that different colon cancer cell lines had 
differential sensitivity to resveratrol, which may be partially due to the different genetic 
background of these cells. 
The cause of colon cancer has been shown to be a complex process which involves 
sequential accumulation of genetic mutations in tumor suppressor genes and oncogenes. One 
the the earliest events in the development of colorectal cancer is the occurrence of an APC 
mutation. APC plays an important role in the Wnt signaling pathway. Mutations in APC 
usually produce a truncated APC protein that causes ~-catenin accumulation, which in turn 
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transactivates ~i-catenin/ Tcf 4 downstream genes such as c-myc and cyclin D 1, and promotes 
cell proliferation (Kioussi et al., 2002; Sancho et al., 2004). The best known tumor 
suppressor gene is p53, which is important in the regulation of cell growth, cell cycle and cell 
death in response of DNA damage, virus infection, hypoxia and other stress signals within 
the cell (Vogelstein at al., 2000). The DNA mismatch repair (MMR) genes, which are 
responsible for recognizing and correcting DNA base pair mismatches that occur during 
DNA replication, are also very important in the process of carcinogenesis. 
The objective of our study is to test the hypothesis that tumor suppressor genes such 
as p53, APC and hMLH 1 are important in modulating resveratrol's growth inhibition effect. 
We are interested in investigating whether the restoration of full length APC in HT29 cells 
and or a proficient MMR system in HCT 116 cells will make them more resistant to 
resveratrol treatment, and if knocking out wild type p53 in HCTl 16 cells will make the cells 
more sensitive to resveratrol. 
In doing this, we studied the role of the APC gene in resveratrol's growth inhibition 
and cell cycle arrest effects by using HT29-APC cells, in which a Zinc inducible wild type 
APC gene was stably transfected into human colon HT29 cells, and a control colon cell line 
HT29-GAL, in which a ~-galactosidase gene was transfected into the cell. HCT116 p53-/-
cell line, in which both p53 alleles were disrupted by targeted homologous recombination, 
and HCTl 16 p53+/+, which has wild type p53, were used to investigate whether deletion of 
tumor suppressor gene p53 will make the cells more sensitive to resveratrol. HCTI 16+chr3 is 
a cell line that has proficient MMR system. We compared HCT 116+chr3 with MMR 
deficient HCT116 cells to study the function of MMR in resveratrol's cell growth and cell 
cycle arrest effect. 
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Thesis Organization 
This thesis contains three chapters. The first chapter is general introduction and 
literature review. The second chapter is a manuscript entitled "Resveratrol inhibits cell 
growth and induces cell cycle arrest in human colon cancer cells independent of tumor 
suppressor genes p53, APC and hMLHl" which will be submitted to Molecular 
Ca~cinogenesis. The third chapter is general conclusions. Literature cited in chapter one and 
three is listed in alphabetical order according to the author's name and literature cited in 
chapter two is listed in the order in which they appear, so as to confirm with the journal's 
requirement. 
Literature Review 
Colon cancer and diet 
Diet and nutritional factors are important in the risk of cancer. Several 
epidemiological studies have indicated that high intake of red meat and fat are positively 
associated with increased cancer incidence, while a diet rich in fruit and vegetables tends to 
lower cancer risk (Steinmetz and Potter, 1991; Giovannucci and Willett, 1994). Steinmetz et 
al found that intake of all fruit and vegetables were inversely associated with lung cancer risk 
in a cohort study in Iowa women (Steinmetz et al., 1993). The inverse relationship of fruit 
and vegetable consumption and colon cancer risk was also observed in women in a Cohort 
Study in the Netherlands (Voorrips et al., 2000). The substances present in vegetables and 
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fruit that may account for their cancer preventive effect may include vitamins, various 
phytochemicals, and dietary fiber (Potter and Steinmetz, 1996; Steinmetz and Potter, 1996). 
Phytochemicals are naturally occurring biochemicals, including phenolics, phenolic acids, 
flavonoids and carotenoids (Waladkhani and Clemens, 1990. They are rich in frequently 
consumed foods such as fruits, vegetables, grains, and seeds. The cancer preventive effect of 
phytochemicals has been studied intensively both in vivo and in vitro. 
In the United States, colorectal cancer is the third leading cause of deaths among 
cancer related diseases (Edwards et al., 2005). Prevention and early detection are considered 
to be key factors in controlling colorectal cancer. Studies from epidemiology have shown that 
dietary factors are important in the prevention of colorectal cancer. The knowledge of DNA 
damage and gene mutation at the cellular and molecular level provide us further information 
on the mechanism of colorectal cancer initiation and progression as well as the association of 
cancer incidence and dietary habits. 
Colon cancer 
Colorectafl carcinogenesis is a multistep process. It involves a series of well 
characterized histopathological changes and sequential genetic alterations (figure 1). 
Oncogene ki-ras and tumor suppressor genes APC, SMAD and p53 are found to be the major 
targets of these genetic changes (Kinzler and Vogelstein, 1996). 
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Figure 1 Colon Carcinogenesis Model (Fodde, 2002) 
"Tumor suppressor genes refer to those genes whose loss of function results in the 
promotion of malignancy" (Osborne et al., 2004). Typically, the normal function of tumor 
suppressor genes is to inhibit cellular proliferation. Mutations of these genes usually result in 
the loss of their growth inhibition ability, which in turn favors cell proliferation. "Oncogenes 
refer to genes whose activation can contribute to the development of cancer" (Osborne et al., 
2004). They are mutated versions of normal cellular genes, pro-oncogenes, which function in 
cell proliferation and differentiation. Expression of oncogenes will cause cells to grow out of 
control. Another group of genes that are important in carcinogenesis are DNA repair genes, 
such as Base Excision Repair (BER), nucleotide excision repair (NER) and Mismatch Repair 
(MMR). Mutations of these genes usually result in genetic instability (Hoeijmakers, 2001). 
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Tumor suppressor gene APC 
One of the early events in the development of colorectal cancer is the inactivation of 
the adenomatous polyposis soli (APC). The APC gene, located at chromosome Sg21-22, was 
first isolated and identified in familial adenomatous poplyposis (FAP), an inherited disease 
which is characterized by the development of hundreds of colorectal adenomatous polyps 
(Groden et al., 1991; Joslyn et al., 1991; Kinzler et al., 1991). Germline mutations of APC 
gene in humans are in part responsible for the initiation of colon adenomas. The APC 
mutations were also found in over 60% of sporadic colonic tumors and in other types of 
cancers, such as breast cancer (Furuuchi et al., 2000). 
The APC gene consists of 8535 base pairs, which encodes 2843 amino acids (Kinzler 
et al., 1991). It has 16 exons, with exon 15 being the most common target for both germline 
and somatic mutations (Nishisho et al., 1991). Most of the APC mutations lead to the 
production of truncated protein (Nagase and Nakamura, 1993). The APC gene has two 
promoter regions, 1 A and 1 B (Lambertz and Ballhausen, 1993). Hypermethylation of 
promoter region 1 A, which results in failure of APC gene transcription, has been found in 
both colorectal adenomas and carcinomas, but not in normal colon mucosa (Esteller et al., 
2000). 
The major molecular function of APC protein is in the Wnt signaling pathway. APC 
is able to bind to Axin and ~-catenin to form a complex, which favors the binding of protein 
kinases CKl a and GSK-3 and phophorylation of ~3-catenin. Phophorylated R-catenin will 
then be ubiquitinated and degraded by proteosome (Su et al., 1993; Rubinfeld et al., 1996). 
The degradation of ~3-catenin is inhibited when APC is inactivated or when Wnt proteins bind 
to receptor Fz/LRP, Disrailed/ HSPG, which promote the direct interaction of Dishevelled 
(Dsh) and Axin (Polakis, 2000). Therefore, ~-catenin is accumulated and translocated into 
nucleus. It then interacts with Lymphoid enhancer-binding factor 1 (LEF 1), T-cell specific 
transcription factor (TCF) or Pitx2 to control downstream gene expression (Kioussi et al., 
2002; Sancho et al., 2004). The targeted genes include c-myc, cyclin D, ephrins, and 
caspases. C-myc, is a proto-oncoprotein, that functions as a transcriptional factor. It is 
involved in the regulation of cell proliferation, differentiation and apoptosis (Luscher, 2001). 
cyclin D, which binds and activates its cyclin dependent kinase partner, is crucial for cells to 
progress though Gl phase (Baldin et al., 1993). Therefore, loss of APC function involves 
changes of cell proliferation and differentiation by the nuclear accumulation of ~i-catenin and 
consequential over-expression of proteins such as c-myc and cyclin D. 
APC protein was found to impact cell migration by changing of cytoskeletal 
regulation that affects microtubules and F-actin (Munemitsu et al., 1994). Cells with mutated 
APC showed disordered migration and prolonged residence in the gut. The prolonged 
residence in the gut is thought to contribute to cell transformation in colon epithelial cells 
(Wong et al., 1996). Studies showed that APC may also regulate the process of chromosome 
segregation, and mutations in APC are capable of inducing chromosome instability (Fodde et 
al., 2001). 
APC is also involved in apoptosis. APC mutations were found to be correlated with a 
decrease in caspase activation. Restoration of wild type APC in colon cancer HT29 cells, 
which has truncated APC, resulted in induction of apoptosis (Morin et al., 1996). caspase 
was found to be one of ~-catenin/TCF complex targets. The expression of caspase was 
negatively regulated by /~-catenin/TCF, and transient transfection with the dominant negative 
TCF/LEF constructs in HT29 cells resulted in increases of caspase 3 and 7 protein expression 
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(Chen et al., 2003). Studies by Steigerwald et al also showed that APC-induced apoptosis 
could also be independent of ~-catenin and the WNT pathway (Steigerwald et al., 2005). 
In order to investigate the function of tumor suppressor gene APC, an in vitro model 
was established in which human colon cancer cell line HT29, which has APC mutation, was 
stably transfected with a zinc inducible wild type APC vector. A (3-galactosidase gene was 
used as a control in this model (Morin et al., 1996). Morin et al. (1996) found induction of 
full length APC expression with zinc inhibited cell growth and induced apoptosis in 
HT29-APC cells. It was also found that both the mRNA and protein of oncogene c-MYC was 
reduced in HT29-APC cells 9 hours after zinc induction compared to that of the control cell 
line HT29-GAL (He et al., 1998). Chung et al treated both HT29-APC and HT29-GAL cells 
with a dietary flavonoid, apigenin, and growth inhibition and G2/M cell cycle arrest was 
observed in both of the cell lines. After inducing full length APC expression, the 
apigenin-induced G2/M arrest in HT29-APC cells was abrogated while there was no changes 
of cell cycle distribution in HT29-GAL cells before and after treatment with zinc. The study 
suggested that cells with mutated APC gene were more sensitive to apigenin in inducing 
G2/M cell cycle arrest than cells with wild type APC gene (Chung et al., unpublished). In the 
current study, we used the HT29-APC and HT29-GAL cell lines to determine the impact of 
tumor suppressor gene APC on resveratrol induced cell growth inhibition. 
Tumor suppressor gene p53 
The p53 gene, also known as "guardian of the genome", was first discovered in 1979 
and identified as a tumor suppressor in 1989 (Lane and Crawford, 1979; Kress et al., 1979; 
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Chang et al., 1979; Baker et al., 1989; Finlay et al., 1989; Eliyahu et al., 1989). Mutations of 
p53 were found in more than half of human tumors (Hollstein et al., 1991). The p53 protein 
plays an important role in the inhibition of tumor development by arresting cells at the G 1 to 
S transition or in G2/M of the cell cycle, and /or inducing programmed cell death (Vogelstein 
et al., 2000). 
p53 is activated upon stress signals, such as gamma irradiation, Uv light, hypoxia, 
virus infection, and DNA damage. The activation of p53 is found to be though several 
pathways at the level of degradation, stabilization and post translational modification. When 
there is DNA damage in the cells, some protein kinases, such as ATM (ataxia telangiectasia 
mutated) and Chk2, are activated. These kinases are able to phosphorylate p53, which in turn 
enhances the binding of p53 to DNA (Carr, 2000). MDM2, a negative regulator of p53, has 
been studied extensively. MDM2 is one of the p53 targeted genes and the synthesis of the 
MDM2 protein is stimulated by p53 (Piette et al., 1997). The MDM2 protein then binds to 
p53 and promotes the addition of ubiquitins to the carboxy terminus of p53, which leads to 
p53 degradation. p53 may also be activated by p 14~F, which is a negative regulator of 
MDM2 (Sherr and Weber, 2000). p 14~F may form a protein complex with MDM2 and 
therefore inhibit p53 degradation. It was found that the transcription of p 14`~F gene is 
induced by a variety of oncogenic signals, such as c-Myc, Ras, E2F-1 and adenovirus E 1 A 
(Palmero et al., 2002; Berkovich et al., 2003). 
The major function of p53 is to bind to specific DNA sequences and regulate gene 
transcription. Several dozen p53 regulated genes have been identified, such as p21 cIPI/WAFI 
MDM2, GADD45, Cyclin G, 14-3-36, Noxa, P53AIP 1 and PUMA. p53 is able to arrest cells 
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at the G1 to S transition or in G2/M of the cell cycle by stimulating the expression of 
p21cIPIn'v`~I, a CDK inhibitor (Gartel et al., 1996) . In addition, p53 also activates the 
transcription of 14-3-36, which binds to the cyclin B1- Cdkl complex and sequesters them 
outside the nucleus and thereby arrests cells in G2 (Chan et al., 1999; Laronga et al., 2000). 
p53 can induce pro-apoptotic proteins such as Noxa, P53AIP1, PUMA directly, or may cause 
cell death by stimulating mitochondria to produce reactive oxygen species in a 
transcriptional- independent manner (Villunger et al., 2003). 
Researchers in Dr. Vogelstein's lab constructed a stable transfected cell line HCT116 
(p53-/p53-), in which both p53 alleles were disrupted by targeted homologous recombination 
and HCT116 (p53+/+) cells which have wild type p53 (Benz et al., 1998). Bunz et al., (1999) 
found that disruption of p53 in HCT116 cells sensitized the cells to the DNA- damaging 
agent adriamycin or irradiation induced apoptosis. The author also observed that HCT 116 
(p53-/-) cells were more resistant to the tumor therapeutic agent 5-fluorouracil than HCT116 
(p53+/+) cells, and the changing of sensitivity to 5-fluoronuracil was independent of p21 
(Bunz et al., 1999). Studies by Mahyar-Roemer et al. (2001) showed that the resveratrol- 
induced apoptotic effect was the same in HCT116 cells with disrupted p53 or wild type p53. 
It was concluded that resveratrol- induced apoptosis was independent of p53 in human colon 
cancer HCTI 16 cells. In the present study, we assessed whether resveratrol induced growth 
inhibition and cell cycle arrest were p53 dependent using the same HCT116 (p53-/-) and 
HCT116 (p53+/+) cell lines. 
DNA mismatch repair (MMR) 
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The MMR pathway is responsible for removing base mismatches generated in DNA 
replication. The MMR system includes a group of homologous proteins such as MSH2, 
MSH6, MLHl, which cooperate with each other in the process of correcting base mismatches 
(Kunkel and Erie, 2005). Briefly, MutSa complex, a heterodimer of MSH2 and MSH6; and/or 
MutS~, a complex of MSH2 and MSH3; are responsible for mismatch recognition and binding 
to DNA (Fishel et al., 1993; Umar et al., 1994; Palombo et al., 1995; Palombo et al., 1996; 
Genschel et al., 1998). After binding to DNA, MutSa associates with MLH 1 and PMS2 
heterodimer, also known as MutLa complex, to recruit exonuclease for base excision and 
DNA polymerase for new synthesis (Li and Modrich, 1995; Papadopoulos and Lindblom, 
1997). 
The MMR system is important in reducing mutations in replication and maintaining 
genomic stability. MMR deficiency is one of the characteristics of human hereditary 
nonpolyposis colorectal cancer (HNPCC) (Leach et al., 1993; Heinen et al., 2002). It was 
found that hMLHl is mutated in about 50% of HNPCC and transcriptionally silenced in 25% 
of sporadic colon tumors (Cej ka et al., 2003 ). Mutations in MLH 1 or MSH2 will lead to 
microsatellite instability. Genes whose coding region is associated with microsatellite DNA 
include TGFbRII, ILGF, E2F-4 and BAX. MMR proteins are activated after DNA damage, 
and may cooperate with p53 to regulate cell cycle and apoptosis (Aquilina et al., 1999; Lin et 
al., 2001). Studies showed that cells with proficient MMR will arrest in G2 though the 
activation of ATM and ATR when treated with DNA methlylating agent, such as 
N-methyl-N-nitro-N-nitrosoguanidine (1~7NNG). 
In the studying the MMR system, a MMR proficient cell line HCT 116+chr3 were 
constructed by transfecting a single chromosome 3 into HCT 116 cells to restore hMLHl 
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expression (Hawn et al., 1995). It was found that cells with deficient MMR (HCTI 16) were 
resistant to DNA damage agent and restoration of wild type MMR proteins hMLHI 
(HCT116+chr3) increased the cells sensitivity (Hawn et al., 1995; Magrini et al., 2002; Stojic 
et al., 2004). In the present study, we compared the response of MMR-deficient cells 
(HCT116) and MMR-proficient cells (HCT 116 + chr3) to resveratrol treatment to find out 
whether the expression of wild type MMR plays an important role in the cellular regulation 
effect of resveratrol. 
Oncogene Ras 
Ras proteins are small GTP-binding proteins, which function in the intercellular 
signaling. Stimulated by external signals, such as cytokines and growth factors, the Ras 
proteins are activated and changed into GTP-bound form by guanine exchange factors 
(GEFs). The activated Ras protein is inactivated by GTP hydrolysis by GTPase activating 
proteins (GAPS) when the external stimulation is gone. Ras can stimulate downstream 
signaling though several pathways. The most studied is the Ras/Raf pathway. Activated Ras 
is able to phosphorylate Raf, a serine-threonine kinase, leading to the activation of 
mitogen-activated protein kinase (MAPK) pathway through the phosphorylation and 
activation of MAPK kinase (MAPKK). Activation of MAPK pathway may promote 
proliferation, differentiation, and induce or inhibit apoptosis depending on the cell type and 
stimuli (Ory and Morrison, 2004). Ras also regulates phosphatidylinositol3-kinase (PI3K) 
pathway and PKB/AKT pathway, through which Ras inhibits apoptosis by inactivation of the 
apoptotic proteins caspase 9 and BAD (Cardone et al., 1998; Part et al., 2002). Other 
downstream effectors of Ras also include RALGDS and PLC (Feig et al., 1996). 
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Oncogenic Ras gene mutation has been found in 30-50% of colon cancers (Bos et al., 
1987). It was found that Ras gene mutations, particularly at codon 12, 13 and 61, become 
constitutively activated, while wild type proteins can be inactivated and changed back to 
GDP bound form by GAP after the stimulation. The constitutive activation of Ras will lead to 
cell proliferation and affect the apoptotic pathway (Macaluso et al., 2002; Cox and Der, 
2003) . 
Cell cycle and apoptosis 
The cell cycle is divided into four different stages: G1 (Gapl), S (Synthesis), G2 (Gap 
2) and M (Mitosis) (fig 2). Cells start to grow at the first stage (G1, Gapl). Then DNA is 
synthesized in the next phase (S). In G2, the cells check whether DNA replication is 
completed and continue to grow, being ready for cell division. The chromosomes are 
separated and finally the cell divides into two daughter cells in mitosis. After division, the 
cell cycle completes and the cells are back in G1 or exit from the cell cycle, and rest in a 
stage called G0. 
The cell cycle is regulated by cylins and cyclin dependent kinase (Cdks). D type 
cyclins and their catalytic partners Cdk4 and Cdk6 act early in G1 phase. Mitogens, such as 
growth factors, induce signal transduction and activate cyclin D—Cdk complexes by 
increasing cyclin D transcription, translation and stability, assembly of D cyclins with their 
Cdk partners, and import of the holoenzymes into the nucleus (Sherr and Roberts, 1999). 
Overexpression of cyclin D1 is known to be associated with human tumorigenesis and 
cellular metastasis (Fu et al., 2004). Downstream of cyclin D-dependent kinases are Rb 
family proteins (Rb, p107, and p130). Cyclin D-Cdk can phosphorylate Rb, which will then 
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dissociate with E2F. E2F is a transcription factor which leads to the synthesis of proteins 
needed for DNA synthesis. Genes that are regulated by E2F include enzymes involved in 
nucleotide synthesis and DNA replication, and cell cycle (Nevins, 1998). 
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Figure 2. Illustration of Major Events in Cell Cycle 
http://nobelprize.org/medicine/laureates/2001 /press.html 
Cyclin E is one of the E2F regulated genes. It binds and activates Cdk2. 
CyclinE-Cdk2 then phosphorylates Rb, releasing E2F and promoting cells into S phase 
(Sherr and McCormick, 2002). In S phase, cyclin A, which is regulated by E2F, associates 
with Cdk 2 to phosphorylate enzymes that start DNA replication (Yam et al., 2002; Woo and 
Poon, 2003 ). Cyclin B is a key regulatory protein in the control of G2/M transition. It binds 
to and activates Cdk 1 (also known as cdc2) in early G2. Activated Cdk 1 phosphorylates a 
variety of target proteins, such as nuclear lamins, Histone H 1, MAPS. The proteins induce the 
assembly of the mitotic spindle, triggers chromosome condensation, nuclear envelope 
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breakdown, actin cytoskeleton rearrangement, and the reorganization of the Golgi apparatus 
and endoplasmic reticulum, leading to cell division (Porter and Donoghue, 2003). 
The number of cells of an organ is determined by cell division, cell death and cell 
migration. Cell death can occur by necrosis, an unordered form of cell death, which usually 
results in leaking of cell content and inflammation, or programmed cell death, apoptosis. 
Apoptosis is highly regulated and involves a series of arranged morphological and 
biochemical events (Adams, 2003). It is important for maintenance of tissue homeostatsis, 
embryo development and effective immune defense. Defects in apoptosis are thought to 
contribute to a number of human diseases, such as neurodegenerative disorders and cancer 
(Gerl and Vaux, 2005; Lossi et al., 2005). 
Two primary signaling pathways have been found to be involved in apoptosis in 
mammalian cells. The first one is known as mitochondrial pathway or intrinsic pathway 
(Duque-Parra, 2005). Briefly, in response to DNA damage, defective cell cycle or oxidative 
stress, the pro-apoptotic Bcl-2 family of proteins is activated and causes the mitochondria to 
release apoptogenic factors, such as cytochrome c and Smac into the cytosol (wang, 2001). 
Cytochrome c is able to bind APAF, forming apoptosome to activate caspase-9, which in turn 
activates caspase-3, -6 or -7. These caspases activate poly (ADP-ribose) polymerase and a 
number of other proteins which in turn result in DNA fragmentation (Zhivotovsky, 2003). 
The second primary pathway of apoptosis is through death receptors on the cell 
membrane. This pathway is also called the extrinsic pathway. Death receptors usually have 
an extracellular cysteine-rich domain which is used for ligand binding and an intracellular 
domain. Death receptors include tumor necrosis factor-receptor 1(TNF-Rl ), Fas/CD95 
receptor and TNF related apoptosis inducing lignad receptor (Debatin and Krammer, 2004). 
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Binding of death ligands, such as tumor necrosis factor a (TNF), Fas-ligand (FasL), 
Lymphotoxin (LTa) or TNF related apoptosis initiating liganc~ (TRAIL) will recruit adaptor 
proteins FADD and procaspase-8 to form adeath-inducing signaling complex and activate 
caspase-8 (Khosravi-Far and Esposti, 2004). Then activated caspse-8 will directly activate 
caspse-3 or cleave Bid, a Bcl family protein. The cleaved Bid (tBid) then transfers from the 
cytosol to the mitochondria membrane and induces cytochrome c release, therefore activating 
the mitochondria pathway (Gupta, 2001). 
Overall, the development of colon cancer is a complex process. It involves the 
accumulation of genetic mutations in tumor suppressor genes and oncogenes, which lead to 
inreased cell proliferation and abnormal programmed cell death in the cells. 




Figure 3 Structure of resveratrol 
Resveratrol, 3, 5, 4'-trihydroxystilbene, is a naturally occurring plant compound. It 
can be found in cis or Mans configurations, or in glycosylated form as resveratrol glucoside, 
which is also called picied. Mans-resveratrol is believed to be more bioactive than the other 
isomers and has been studied most intensively. The chemical structure of Mans-resveratrol is 
shown in figure 3. 
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Resveratrol was identified as an active constituent in dried roots of Itadori plant 
Polygonum cuspidate, in grapes and red wine (Nonomura et al., 1963 ; Langcake and Pryce, 
1976; Siemann and Creasy, 1992). The amount of resveratrol in red wine varies, ranging 
from 0.02-13.4 mg/L, and tuns-resveratrol is found to be the predominate form in red wine 
(Fremont, 2000). Grapes and Itadori plant mainly contain Mans-resveratrol glucoside, with 
concentrations ranging from 1.5 to 7.3 µg/g, and from 83 to 2170 µg/g respectively (Burns et 
al., 2002). Other plants that were found to have resveratrol include peanuts, eucalyptus, 
spruce, lily, mulberries and groundnut (Sobolev and Cole, 1999; Sanders et al., 2000; Lyons 
et al., 2003; Rimando et al., 2004). 
The intake of resveratrol comes from various dietary sources including red wine, 
grapes and peanuts. The dietary intake of resveratrol was estimated to be around 18 µg/Kg in 
a 70 Kg person taking moderate amount (250 ml) of red wine, which contains 5 mg/L 
resveratrol (Gescher and Steward, 2003). In addition, resveratrol supplements are also 
commercially available. Various products contain different amount of resveratrol, ranging 
from less than 1 mg to 20 mg per tablet. 
The dried roots of Itadori plant have been used as folk medicine in China and Japan to 
treat inflammatory, hypertensive, allergic and lipid disease for centuries. Many studies have 
shown that Mans-reveratrol has antioxidant, anti proliferation and anti-inflammatory activity 
(Manna et al., 2000; Martin et al., 2004). tuns-resveratrol is believed to be effective in 
prevention of cardiovascular disease, modulating immune response and it has 
neuroprotective and cancer preventative activities (Jang et al., 1997; Lin and Tsai, 1999; Han 
et al., 2004). Mans-resveratrol aglycone is referred as resveratrol in the rest of the paper. 
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The effect of resveratrol in colon cancer 
Colorectal cancer has a high death rate among cancer related diseases in the United 
States (CDC). The chemopreventive effects of resveratrol in colon cancer have been studied 
both in colon cancer cells and in animal models. Resveratrol was found to inhibit cell growth, 
arrest cell cycle at S or G2M phase and induce programmed cell death in several human 
colorectal cell lines Caco-2, SW480, HT29, and HCT116 (Delmas et al., 2002; Wolter et al., 
2002; Liang et al., 2003). 
Resveratrol was found to reduce the number of ACF in AOM treated rodents. 
Tessitore et al (2000) found that administering resveratrol in drinking water at a dose of 200 
µg/kg body weight/ day for 100 days in male F344 rats reduced the number of aberrant crypt 
foci (ACF) and their multiplicity induced by azoxymethane (AOM). In the same study, 
resveratrol was found to increase pro-apoptotic protein Bax in ACF but not in the 
surrounding mucosa. The author also found that the level of p21 in normal mucosa was 
elevated when the animals were treated with AOM. The increased expression of p21 was 
abolished after resveratrol administration (Tessitore et al., 2000). A recent study in the Birt 
lab showed that resveratrol was effective in reducing the number of ACF in AOM treated 
CF-1 mice at a dose of 0.002% of diet, which is about 2.4 mg /kg body weight/day, for five 
weeks (Kineman et al., unpublished). 
The chemopreventive effect of resveratrol has also been studied in Min (multiple 
intestinal neoplasia) mouse and the results were not consistent. Min mice, which have genetic 
colon cancer caused by mutant APC, are a model that is used for the study of human familial 
adenomatous polyposis. Schneider et al (2001) treated Min mice with 0.01 %resveratrol in 
drinking water containing 0.4% ethanol for seven weeks. The dose is estimated to be 12 to 16 
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mg/kg body weight/day (Ziegler et al., 2004). The results showed that resveratrol inhibited 
the formation of tumors in the small intestine by 70%. By using cDNA expression arrays, the 
author found that genes that function in cell proliferation, such as cyclin D 1, cylin D2, DP-1 
transcription factor and Y-box binding proteins were downregualted by resveratrol, while 
some genes that are involved in the immune system, such as cytotoxic T lymphocyte Ag-4 
and leukemia inhibitory factor inhibitor, were upregulated (Schneider et al., 2001). Sale et al 
(2005) fed Min mice with 0.2% and 0.05% resveratrol in the diet, which is equivalent to 240 
mg/kg body weight/day and 60 mg/kg body weight/day, respectively, for 18 weeks. It was 
found that the mean adenoma numbers in resveratrol (0.2% in the diet) treated mice were 
27% lower than those of mice not treated with resveratrol. No significant effect was observed 
for the lower dosage, 0.05% resveratrol in the diet (Sale et al., 2005). In another study with 
the Min mouse model, resveratrol was found to not inhibit tumorgenesis when the animals 
were given resveratrol in the diet in a dose 4, 20 or 90 mg/kg body weight/day for seven 
weeks (Ziegler et al., 2004). In the same study, PGE2 levels in tumors of mice fed with 90 
mg/kg/day resveratrol were lower than that of control mice, however, the expression of 
COX-2 protein was not changed. 
The major rodent models used in the study of resveratrol on colorectal cancer have 
been the AOM rodent model and Min mouse model. It is known that efficacy of a 
chemo-preventive agent may not be always consistent in different species, (human vs rodent, 
rat vs mouse), different stains within same species (CF-1 mice vs Min mice) and different 
routes of administration such as diet vs drinking water. In the AOM model, resveratrol was 
effective in prevention of ACF formation either in rat or mice, though drinking water or in 
the diet. The effective dose of resveratrol in AOM model was 0.2 mg/kg body weight/day for 
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F334 mice and 2.4 mg/kg body weight/day for CF-1 mice respective. However, resveratrol 
was not effective in prevention of tumor formation in two out of three studies in the Min 
mouse model when the dose was less than 90 mg/kg body weight/day, irrespective of the 
administration route. Therefore, it seems resveratrol was more effective in prevention of 
tumorgenesis in AOM rodent model than Min mice model. 
Studies showed that AOM-induced tumors in rodents often have mutated Ki-Ras and 
13-catenin genes, but less frequently contain mutations in the APC gene. On the contrary, Min 
mice that have mutated APC gene seem to seldom have Ki-Ras mutation (Shoemaker et al., 
1997). It seems that the different sensitivity to resveratrol treatment observed in AOM mouse 
model and Min mouse model could be related to their different status of specific mutations. 
APC, p53 and Ki-Ras are mutations that are commonly observed in human colon tumors. 
The effect of resveratol in cell growth, cell cycle and cell death 
Revveratrol was found to inhibit cell growth, arrest cell cycle at S or G2M phase and 
induce programmed cell death in a number of human colorectal cell lines. 
Studies in human colon cancer Caco-2 cells showed that the cell growth was inhibited 
about 70% when the cells were treated with 25 µM resveratrol for 48 hours (Schneider et al., 
2000). It was found that cells accumulated in S phase after incubation with 25 µM resveratrol 
for 16 and 24 hours. A significant decrease of ornithine decarboxylase (ODC) activity was 
observed after resveratrol treatment. However, the activity of adenosylmethione 
decarboxylase, an enzyme that functions in polyamine biosynthesis with ODC, was not 
changed. At the same time, the concentration of spermidine in Caco-2 cells was significantly 
decreased probably due to the decrease of ODC. 
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Another study with Caco-2 cells found that resveratrol significantly inhibited cell 
proliferation at 25 µM and cells accumulated in S phase after 24 hours treatment with 50 µM 
resveratrol (Wolter et al., 2001). There was a significant decrease of cyclin D 1 and cdk4, 
while the expression of cyclin E was found to be increased. No changes were found in 
PCNA, cdc2, cdk2 or cdk6. In addition, retinoblastoma protein was shifted from the 
hyperphosphorylated to the hypophosphorylated form by the treatment of resveratrol. When 
the cells were treated with 200 µM resveratrol for 24 and 48 hours, caspase-3 activity was 
significantly elevated. 
SW480 is a human colon cancer cell line, which has p53, ki-ras and APC mutations 
and has been used in the study colon cancer. Joe et al (2002) treated SW480 cells with 200 
µM resveratrol for 24 hours. They observed that most of the cells arrested in the S phase of 
the cell cycle. Cylin A, cyclin B 1, Cylin D 1 and beta-catenin expression levels were inhibited 
by the treatment of resvetrol. Resveratrol was found to decrease cyclin D 1 mRNA levels at 
3 00 µM, however, it did not block cyclin D 1 promoter activity as shown by luciferase 
reportor assay(Joe et al., 2002). 
Delmas et al (2002) also investigated the effect of resveratrol in SW480 cells. It was 
found that resveratrol was able to inhibit cell proliferation by 50% at 30 µM after 24 hours 
treatment. A significant growth inhibition was observed as low as 5µM, when the cells were 
treated with resveratrol for three days. Studies of cell cycle distribution by flow cytometry 
showed that resveratrol induced an S phase accumulation. DNA synthesis was found to be 
increased by [3H]-thymidine incorporation and BrdU incorporation experiments. Western 
blot analysis showed that the protein level of cyclin A, cylin B 1, cdk 1 and cdk2 were 
increased by resveratrol. The amount of phosphorylated Ckl was also found to be increased. 
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The results implied that resveratrol induced S phase accumulation was due to a delay of the 
cell cycle that prevents the cells from entering G2M phase rather than an inhibition of DNA 
synthesis (Delmas et al., 2002). 
The growth inhibition effect of resveratrol was also studied in HT29 cells, a colon 
cancer cell line with mutated APC and p53 (Liang et al., 2003). Resveratrol was found to 
inhibit cell growth at 50 µM by the colony growth assay. The DNA synthesis was reduced to 
50% of control according to the [3H]-thymidine incorporation assay when cells were treated 
with 100 µM resveratrol for 24 hours. It was found the cells were blocked at G2 phase of the 
cell cycle. The protein level of cyclin A, cyclin B 1 and the inactive form of p34 (CDC2) was 
elevated by reveratrol while the kinase activity of p34 (CDC2) and CDK 7 was inhibited 
(Liang et al., 2003). Sale et al (2004) treated HT29 cells with resveratrol for seven days. 
They found that cell growth was significantly inhibited by resveratrol as low as 20 µM (Sale 
et al., 2004). 
HCTI 16 colon cancer cells have wild type p53 and APC genes, but have mutant 
Ki-ras. Studies showed that 50 µM resveratrol was able to inhibit cell proliferation and 
induce cell cycle arrest at S phase (Wolter et al., 2002). Analysis of cyclins and Cdks showed 
that resveratrol decreased the expression of Cyclin D1, cdk4 end Cdk inhibitor p27 KIPI, 
increased the expression of cyclin E and had no effect on Cdk2 and Cdk6. 
Studies on resveratrol induced apoptosis were also conducted in various colon cancer 
cell lines. No apoptosis was detected by DNA fragmentation assay when Caco-2 cells were 
treated with 25µM or 50 µM for 24 or 48 hours as shown by Schneider et al (2000). Wolter et 
al (2002) treated Caco-2 cells with 200 µM resveratrol for 24 and 48 hours and observed a 
significant elevation of caspase-3 activity. 
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Mahyar-Roemer et al (2001) showed that resveratrol-induced apoptosis in HCT116 
cells at 100 µM. Increasing the percentage subG01 in cell cycle, changing of mitochondria 
potential, releasing cytochrome c and activation of caspase 9 was also observed in the same 
study. This study indicated that resveratrol-induced apoptosis was through a mitochondria- 
dependent pathway. The author found that resveratrol was able to upregulate the expression 
of pro-apoptotic protein Bax. It was shown later that resveratrol induced mitochondrial 
apoptosis could be both Bax dependent and Bax independent (Mahyar-Roemer et al 2003). 
Studies in the same group also showed that resveratrol induced apoptosis in HCT116 cells 
was independent of tumor suppressor gene, p53 (Mahyar-Roemer and Roemer, 2001; 
Mahyar-Roemer et al., 2001). 
Studies in SW480 cells by Delmas et al (2003) showed that resveratrol was able to 
induce apoptosis at concentrations as low as 10 µM. The induction of apoptosis seems to be 
caspase dependent indicated by the elevation of caspase-3, caspase-8 and caspase-9 enzyme 
activity and the release of cytochrome c with resveratrol treatment at 30 µM for two days. 
Resveratrol increased the protein expression of Bax and Bak and induced Bax redistribution 
in the mitochondria membrane and Fas receptor redistribution into lipid raft in the plasma 
membrane (Delmas et al., 2003). The redistribution and clustering of Fas receptor (CD95) 
was also observed in human colon cancer HCT 116 and HT29 cells, which were more 
resistant to resveratrol induced apopotis than SW480 cells (Delmas et al., 2004). 
Overall, resveratrol inhibited colon cancer cell growth, arrested cells in S and/or 
G2/M of the cells cycle. Resveratrol may induce apoptosis in colon cancer cells through a 
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membrane potential pathway. Death receptors may also be associated depending on specific 
cell type and cellular environment. 
Toxicological study of resveratrol 
Ideally, an effective chemopreventive agent should only kill or inhibit the growth of 
damaged or mutant cells, but have little or no toxicity toward normal tissue or cells. The 
potential toxicity of resveatrol should also be considered especially when it is taken in high 
doses as a supplement. 
Studies in a rat model found that a high dose of resveratrol (1000 mg/kg body 
weight/day) produced nephrotoxicity and mild hepotoxicity. The animals also showed 
labored breathing, decreased activity, diarrhea and reduced body weight gains (Crowell et al., 
2004). The no-observed-adverse-effect-level (NOAEL) of resveratrol was estimated to be 
300 mg/kg body weight/day in these animals. Resveratrol was found to promote 
atherosclerosis in the New Zealand white rabbit when concurrently fed a high cholesterol 
diet. The dosage for the treatment was 0.06 mg/kg body weight during 1-5 days and 1.0 
mg/kg body weight on day 6 to 60 (Wilson et al., 1996). A study by Juan et al found that 
resveratrol had no adverse effect on Sprague-Dawley rats when the animals were 
administrated 20 mg/kg body weight/day for 28 days (Juan et al., 2002). Resveratrol was 
found to be negative in bacterial resverse mutation assay using S typhimuriurn stains TA100 
and TA98 and E. Coli stain WP2uv~A at dose from 0.02 to 5000 µg per plate with or without 
S9 (Matsuoka et al., 2001). In cultured cells, resveratrol was found to induce sister chromatin 
exchanges in Chinese hamster lung (CHL) cells at 2.5-20 µg/ml (10 to 100 µM) in a dose 
dependent manner (Matsuoka et al., 2001). The genotoxicity of resveratrol was observed in 
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L5178Y mouse lymphoma cells by Schmitt et al (2002), in which the micronuclei and 
metaphase chromosome displacement was induced by resveratrol at 60 µM (Schmitt et al., 
2002). A recent study found that resveratrol at 10 µM may induce mutations in Chinese 
hamster V79MZ cells, but not in Chinese hamster V79h1A2 and V79h1B1 cells (Boyce et 
al., 2004). 
Summary 
Resveratrol was found to prevent colon cancer in rodent models and it can inhibit the 
growth of colon cancer cells. Different colon cancer cell lines were found to have differential 
sensitivity to resveratrol. SW480 cells, which have mutant p53, mutant APC, mutant Ki-ras 
are found to be more sensitive than the other cell lines such as HCT 116 and HT29. 
Differential sensitivity to resveratrol was also observed in different animal models and 
resveratrol seems to be more effective in AOM model than Min mice model. In the AOM 
model, which frequently have mutated Ki-ras and 13-catenin genes, but not tumor suppressor 
gene APC, resveratrol reduced AOM induced ACF formation in F334 rat at dose of 0.2 
mg/kg body weight/day through drinking water with 0.3 % alcohol and in CF-1 mice at 2.4 
mg/kg body weight/day in the diet (Tessitore et al., 2000; Kineman et al., unpublished). In 
the studies of resveratrol's cancer preventive effect in Min mice, two studies showed that 
resveratrol had no significant effect in reducing tumors when the dose was lower than 90 
mg/kg body weight/day, while one study showed that resvertrol was effective in reducing 
tumor load at 14 -16 mg/kg body weight/day. Overall, the effective dose observed Min mice 
model was much higher than AOM model. 
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Traditional chemotherapeutic drugs usually affect normal cells as well as cancer cells. 
One approach in chemoprevention is to find agents that kill cancer cells but have no or 
minimum damage on normal cells. In doing this, it is important to compare the effect of 
resveratrol in cancer cells with their normal partners. However, as reviewed above, all the 
studies regarding resveratrol's cancer preventive effect in colon cancer were done either in 
colon cancer cell lines or animal model. The limited number of toxicological studies 
regarding resveratrol used bacteria, animal cells or mice. No studies have been conducted to 
investigate whether there is a differential sensitivity to resveratrol between colon cancer cells 
and normal colon cells. As we know, one of the characters of tumor cells compared to normal 
cells is that tumor cells have lost the normal function of tumor suppressor genes. Various cell 
models, HT29-APC and HT29-GAL cells, HCTl 16 (p53-/-) and HCTl 16 (p53+/+), and 
HCT 116+chr3 (MMR proficient) and HCT 116 (MMR deficient) have been constructed and 
turned. These models are useful tools to study the cancer cells and their partner cell lines in 
which only the status of the targeted gene are different. 
we hypothesize that tumor suppressor genes such as p53, APC and MMR genes are 
important in modulating resveratrol's growth inhibition effect. Thus, restoration of full length 
APC in HT29 cells and proficient MMR system in HCT 116 cells would make these cells 
more resistant to resveratrol treatment. Further more, knock out of wild type p53 in HCTI 16 
cells would make the cells more sensitive to resveratrol's growth inhibition properties. 
The objective of the study is to determine whether mutations in tumor suppressor 
genes in colon caner cells will change the cells sensitivity to resveratrol treatment. My 
studies compared the impact of resveratrol on cell growth and cell cycle in HCT 116 cell 
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with wild type or knock out p53, HT29 cells with or without full length APC and HCTl 16 
cells with proficient or deficient DNA mismatch repair system. 
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CHAPTER 2. RESVERATROL INHIBITS CELL GROWTH AND INDUCES CELL 
CYCLE Al~:REST IN HUMAN COLON CANCER CELLS INDEPENDENT OF 
TUMOR SUPPRESSOR GENES p53, APC, and hMLHl 
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Abstract 
The effect of resveratrol on cell growth and cell cycle was examined in colon cancer cells 
that express wild type or mutant tumor suppressor genes p53, APC and hMLHl. Revveratrol 
arrested cells in the S and G2/M stages of cell cycle and reduced cell number in four 
colorectal cancer cell lines (SW480, HT29, DLD 1, and HCT 116) dose dependently. Further 
studies in SW480 cells showed that the resveratrol-induced cell growth inhibition and cell 
cycle arrest was reversible. When HCT116 cells with wild type p53 and a parallel p53 knock 
out cell line were treated with 0 to 30 µM resveratrol for 24, 48 and 72 hours, the impact of 
resveratrol on growth inhibition and cell cycle arrest was similar in the two cell lines. 
Similarly, when MMR proficient HCT 116+chr3 cells and MMR deficient HCT 116 cells 
were each treated with 30 µM resveratrol they showed comparable G2/M arrest (P<0.05). 
HT29 cells, with inducible expression of full length APC (HT29-APC) and a control cell line 
containing inducible 13-galactosidase (HT29-GAL), were used to evaluate the impact of APC 
on cell cycle arrest by resveratrol. Both cells showed a significant G2/M arrest by 80µM 
resveratrol (p<0.05), and the expression of wild type APC did not alter the cells sensitivity to 
resveratrol. In conclusion, we found that the expression of full length APC in HT29 cells, 
depletion of p53, or restoration of MMR status in HCT 116 cells did not change the effect of 
resveratrol on cell growth or cell cycle. 
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Introduction 
Resveratrol, 3, 5, 4'-trihydroxystilbene, is a biologically active constituent in grapes 
and red wine [ 1-3 ] . Other plants known to contain resveratrol include peanuts, eucalyptus, 
spruce, lily, mulberries, and groundnut [4-7] . The health benefits of resveratrol have been 
studied extensively in recent years and resveratrol was found to have the potential to prevent 
cancer, cardiovascular, and neuronal degenerative diseases [8-10]. 
Colorectal cancer has a high death rate among cancer related diseases in the United 
States. The chemopreventive effects of resveratrol in colon cancer have been studied both in 
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colon cancer cells and in animal models. Resveratrol was found to inhibit cell proliferation 
and induce GO/1, or S and G2/M cell cycle arrest and apoptosis in Caco-2, SW480, HT29, 
and HCT116 colon cancer cells. The results showed that different cell lines may have 
differential sensitivity to resveratrol treatment [11-13]. In animal models, resveratrol was 
found to reduce azoxymethane (AOM) induced aberrant crypt foci (ACF) in male F344 rats 
at a dose of 0.2 mg /kg body weight /day in drinking water and in CF-1 mice at a dose of 2.4 
mg/kg body weight/day in the diet [14,15]. In Min (multiple intestinal neoplasia) mouse 
model in which intestine tumors develop spontaneously due to a mutation in the APC gene, it 
was found that resveratrol reduced the formation of small intestinal tumors in these mice 
when given in the drinking water at 12-16 mg/kg body weight /day, or in the diet at 240 
mg/kg body weight/day [16, 18]. Resveratrol seemed to have no significant effect on 
tumorgenesis in APC'N'n+ mice when the dose was lower than 90 mg/kg body weight/day [17, 
18]. Studies showed that AOM induced tumors in rodents often have mutated Ki-ras and 
(3-catenin genes, and less frequently contain APC mutations. On the other hand, Min mice 
that have mutated APC gene axe found to seldom have Ki-ras mutation [19]. The differential 
sensitivity to resveratrol observed both in animal models and cells lines may be partially due 
to their different genetic background. 
APC mutations axe considered to be one of the earliest events in the development of 
colorectal cancer and they have been found both in sporadic and hereditary colon cancer [20, 
21]. The tumor suppressor gene, APC, has multiple cellular functions including a major role 
in the Wnt signaling pathway. Loss of the normal function of APC will lead to the 
accumulation of free (3-catenin and transactivation of R-catenin/ Tcf 4 targeted genes such as 
c-myc, cyclin D1, and matrix metalloproteins 7 (MMP-7), leading to increased cell 
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proliferation and cell growth [22-25]. In order to determine whether the expression of wild 
type APC in colon cancer cells will make them more sensitive to resveratrol, in the study 
reported here, HT29 cells which have been stably transfected with an inducible wild type 
APC were studied and a cell line, which was transfected with (3-galactosidase, was used as a 
control [26]. 
p53 is a known tumor suppressor gene which plays an important role in the regulation 
of cell growth by arresting cells at the G1 to S transition or in G2/M of the cell cycle and/or 
inducing programmed cell death [27, 28]. Resveratrol has been found to increase p53 protein 
expression and p53 transactivation activity in mouse epidermal cells [29] and to induce 
serine phosphorylation of p53 in human prostate and thyroid cancer cells [30, 31]. In the 
present study, we assessed whether resveratrol induced growth inhibition and cell cycle arrest 
were p53 dependent by using HCT116 (p53-/-) cells in which both p53 alleles were disrupted 
by homogenous recombinant and HCT116 (p53+/+) cells which have wild type p53 [32]. 
The DNA mismatch repair (MMR) system recognizes and corrects DNA base pair 
mismatches that occur during DNA replication. The MMR system includes a group of 
homologous proteins such as MSH2, MSH6 and MLH1, which cooperate with each other in 
the process of correcting base mismatches [33]. MutSa, heterodimer of MSH2 and MSH6, 
and/or MutS(3, a complex of MSH2 and MSH3, are responsible for mismatch recognition and 
binding to DNA. MutLa, a complex of MLHl and PMS2, associates MutSa to recruit 
exonnuclease for base excision and DNA polymerase for new DNA synthesis [34, 35]. MMR 
deficiency is one of the characteristics of human hereditary nonpolyposis colorectal cancer 
[36]. MMR proteins are activated after DNA damage and induce cell cycle arrest in G2 [37, 
38]. HCT116 +chr3 cells were constructed by transfecting a single human chromosome 3 
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into HCT116 cells to restore hMLHI expression [39]. The transfected cells are partially 
proficient in MMR. Studies that compare the response of MMR deficient cells (HCT116) 
with MMR proficient cells (HCT116 +chr3) to resveratrol treatment were conducted to detect 
the impact of MMR proficiency on the growth inhibition effect of resveratrol. 
The objectives of the study reported here were to evaluate the effects of resveratrol on 
the growth and cell cycle distribution of colon cancer cells, and to determine whether 
mutations of the tumor suppressor genes APC, p53, or hMLHI alter these effects. We 
hypothesized that the expression of full length tumor suppressor APC in HT29 cells and 
restoration of MMR status in HCT116 cells would make the cells more resistant to 
resveratrol, while depletion of wild type p53 in HCT116 would make the cells more sensitive 
to resveratrol. 
Meterials and Methods 
Cell culture 
Human colon cancer cell lines SW480, HCT116, DLDl and HT29 were obtained from 
the American Type Culture Collection (Rockville, MD). HT29-GAL, HT29-APC, HCT116 
(p53+/+), and HCT116 (p53-/-) were kindly provided by Dr Bert Vogelstein (The Johns 
Hopkins University, Baltimore, MD). HCT116+Chr3 cell line was a generous gift from Dr 
Richard Boland (University of California, San Diego, CA). 
SW480, DLD 1 cells were cultured in Dulbecco's Modified Eagle Medium (Sigma, St 
Louis, MO) with 10% fetal bovine serum (FBS, Sigma, St Louis, MO), 100 U/ml penicillin, 
and 100 µg/ml streptomysin (Sigma, St Louis, MO). HT29, HCT 116, HCT 116 (p53+/+), and 
HCTl 16 (p53 -/-) cells were cultured in McCoy's SA Modified Medium (Sigma, St Louis, 
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MO) with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. HT29-GAL and 
HT29-APC cells were cultured in McCoy's SA Modified Medium with 10% FBS and 600 
mg/L of hygromycin (Roche, Indianapolis, IN). HCTl 16+Chr3 was maintained in Iscove's 
Modified Dulbecco's Medium (Sigma, St Louis, MO) with 10% fetal bovine serum (FBS, 
Sigma, St Louis, MO) and 400 µg /ml Geneticin (G418, Life Technologies, Rockville, MD). 
All the cells were maintained in a humidified incubator at 37°C with 5% CO2. 
Resveratrol treatment and measurement of cell number 
Resveratrol (Sigma, St Louis, MO) and apigenin (Sigma, St Louis, MO) stock 
solution was prepared in dimethyl sulfoxide (DMSO, Sigma, St Louis, MO), stored at -20°C 
in the dark and added to the cell culture medium, keeping the final concentration of DMSO 
to less than 0.2%. Cells were plated on 6-well plates. Twenty-four hours post plating, when 
cells were about 30-40% confluent, they were treated with 0 to 80 µM reveratrol or 80 µM 
apigenin for 24, 48 or 72 hours. HT29-APC and HT29-GAL cells were treated with or 
without 100 µM ZnCl2 to induce full length APC expression in the HT29-APC cells. After 
treatment, cells were detached from the plates with trypsin (0.25%trypsin, 0.3% EDTA, 
GIBCO) for 2 to 5 minutes. Then fresh culture medium was added to each well to stop the 
trypsin digestion and resuspend the cells. The number of suspended cells was counted with a 
hemacytometer using a microscope. 
Flow cytometry analysis 
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For cell cycle analysis, cells were fixed in 70% cold ethanol and stored at 4°C 
overnight. Then the fixed cells were washed with phosphate buffer saline (PBS) and 
resuspended in 20µg/ml propidium iodide and 1µg/ml RNase in PBS . Flow cytometry 
analysis was performed by a FACStar-plus flow cytometer, with an excitation at 488 nm and 
an emission at 63 0 nm (Becton Dickinson, Franklin Lakes, NJ). 
Western Blot analysis 
To determine the expression of whole length APC protein in HT29-APC and 
HT29-GAL cells, whole cell proteins in lysis buffer (40 mM Tris-HCl pH 7.4, 120mM NaCI, 
2mM EDTA, 2mM EGTA, 0.5% Triton X-100, 1 mM PMSF, 1 OmM sodium pyrophosphate, 
l0ug/ml leupeptin, and Sug/ml aprotinin) were quantified by bicinchoninic acid (BCA) 
protein assay (Sigma, St. Louis, MO). The whole length APC expression was detected by 
western blot analysis using an antibody specific to the C-terminal 3 06 amino acid residues of 
APC protein from Oncogene Research Products (Boston, MA). Sixty micrograms of protein 
were loaded per lane and electrophoresed on a 3 % agarose gel with 1-cm 15 % acrylamide on 
the bottom of the gel. The proteins were transferred to a polyvinyidene difluroide (PVDF) 
membrane by downward capillary transfer overnight. The membrane was blocked for 2h at 
4°C with 10% nonfat dry milk in TBST (20mM Tris base, 137 mM NaCI, pH=7.6, 0.1 
Tween-20) before incubation with 1µg/ml of APC (Ab-2) antibody overnight at 4°C. After 
the membrane was washed, it was incubated with horseradish peroxidase-conjugated goat 
anti-mouse antibody (Santa Cruz biotechnology, Santa Cruz, CA) for 1 h and detected with 
enhanced chemiluminescence detection reagent (ECL plus, Amersham, Arlington Heights, 
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IL). The blot was scanned by a Molecular Dynamics Fluorescence scanning system. Band 
density was quantitated by Molecular Dynamics ImageQuant software and normalized to the 
positive control. 
The detern~.ination of hML:I--I 1 protein in I~CT 11 ~ and I~CT 116+C1~.x3 by western blot 
analysis was si~~nilar to the AFC protein described above, except that fifty micrograms of 
protein were separated o~1 a 7.~% SDA-PACJE gel a~1d elect:~•oblotted to FVDF men~:branes. 
The membrane was incubated with anti I~ILI--I1 antibody for 2 hours at room te~~.perature, 
after blocking with 10% nonfat dry milk in TBST. Similarly, t:he :~nerr~bra~~e was ~vas:hed, 
incubated with horseradish peroxidasemconjugated goat anti-mouse antibody (Santa Cruz 
biotechnology, Santa Cruz, CA) for 1 h, and detected with enhanced chen~.i:lun~i~~escence 
detection reagent (ECL plus, Arnersha~n, A~•lington I~eigl~ts, IL}. 
Statistical Analysis 
Cell number and cell cycle distribution between phases (GO 1, S, G2M) in each cell 
line were analyzed by one-way ANOVA with Tukey's multiple comparison using SAS 9.1. 
The result was considered to be significant if the p value was less than 0.05. Within each cell 
line, the log of cell number and dose was analyzed by linear regression. EC50, the 
concentration at which the cell number is 50% of that of control treated sample, was 
estimated by the linear regression model using R 2.2.0. 
In the study to check whether the growth inhibition and cell cycle effect of resveratrol 
were reversible in SW480 cells, the growth rate of SW480 cells was estimated as the slope of 
the log of the cell number against time by linear regression using SAS 9.1. Cell growth 
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within each group was compared by estimating the difference between the slopes in this 
linear regression model. The growth rates were considered significantly different if the p 
value was less than 0.05. 
In order to compare HCT 116 p5 3+/+ cells with HCT 116 p5 3 -/- cells, HCT 116+chr3 
and HCT 116 cells, the slope of the log of the percentage of G2M against resveratrol 
concentration was estimated and compared by linear regression using SAS 9.1. 
Results 
Irupact aI' resve~ratr+~l ox~ sell ~ro~vth aucl cell c~~cle iu hun~.~n colon c~.ucer cells 
Sw480 cells, DLD ~., HCT:I 1 ~6, a1~d I~T29 cells were tlaeated with r~~edia containing 0 
to 80 µM resveratrol for 4f~ hours. Figure 1 sllows that resveratrol decreased total cell Ilurnbe~• 
i11 a dose dependent n~an:ner i.n all four cell lines tested. For Sw4S0 and DLD 1. cells, the cell 
number v~jas significantly decreased by resveratrol treatment as low as 10 ~M ~P<0.05}, w1111e 
for HCT1. 1. b and I--1:T29 cells signiflcallt decreases in cell I~un~1~e1~ occurl•ed at ?0 µ1't a1~d ~0 
µM, respectively. The EC50, effective concentration at which 50°~~ of growth inhibition is 
observed, was estil~.ated for eacll cell line. It was 14.b -x-- 1.4 ~,M for S'~v4~0 cells, 14.? -E-
1.5 µM for DLD-1 cells, 30.4 -~- 3.2 ~,M for HCTl 16 cells and 93.5 -~-- 1 ~.4 for HT29 cells. 
~~11 of the four cell lines sllo~ved a dose dependent decrease off` cells in C~0/1 and all increase 
of cells i11 S phase and G~/M phase after treatmel~.t with resveratrol as indicated i~l figure 2. 
Resveratrol decreased. the percentage of cells in G~ 1, increase cells in S and./or Cr2M 
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significantly at 10 ~,M for ~w~~o cells, 20 ~,M for D►LI~1 cells and 3Q ~,NI for I-I~.~TI 1~► cells, 
~Oµ.~ for HT~~ cells. 
The growth inhibition ~n€i cell cycle arrest e~'feets o#' res~Te~•~tx•oi in ~~v~~o eeiis ~iTer•e 
re~ersibie 
In order to deter~~ine whether the growth inhibition and cell cycle arrest effect of 
resveratro~. was reversible, eve treated S~v48o cells with ~~.edia contai~~.~.ng 0 ~.~: or 25 ~,:1~ 
resveratrol for ?days. Then half of the plates of ~•esveratrol treated cells were washed twice 
and incubated ~vit.h :~~.edia containi~~g 0 ~,M ~~esveratrol. The other ha:~f of. the resverat:rol 
treated cells anal control cells were treated with fresh media containing the same 
co~~centration of. ~•esveratrol that t%.ey were exposed to du~•i.ng the i~Zitial ;~ day incubatio~~. 
After cells were treated with media containing 25 ~-~ resveratrol for ?days, the total cell 
number ~,va.s less than half of the value for control cells (0 ~.IV1 resveralrol:) as is shown in 
figure 1(a} and figure 3(a~. wl~..er~ we continued to treat tl~e cells with ~5 ~,~ resveratrol, the 
cell number decreased after 2 days of culture and reached a new% lower count at the fou~~th day 
(see figure 3a). The cell Friability also decreased as determined by Trapan Bule exclusion 
assay. :~'o~• cells that were treated with 25 ~~: resveratro:l fo:~f ~ days anal them. changed to 
control medium, the cells reverted to a pattenl of growth. similar to what was observed with 
control cells. Tl~.e cell grawth rate was estir~~.ated as the slope of`the log o#`cell nu:~~.ber 
against time. It was found that the growth rate of 25 ~.~I'~I resverat~•ol treated cells, after 
resveratrol vas removed, vvas not significantly different from the cont~•oI group (p>o. ~ ), 
48 
while the growth rates of bath the above two groups ale significantly different from cells that 
were treated with resveratl-al during the seven day incubation (P~0.000 ~. ). 
when Sw4S0 cells were treated with res~1eratrol for 2 days, the percentage of cells in 
G2/Iii was about 2~% and i.t ~%as sig~.i~cantl.y ~.ighel- than the percentage of CIS/: i.n the 
control cells, r~rllleh ~~vas about 15%. (figure 2a and 3b). when resveratrol treatment 
continued, the percentage of cells in G2iiWI continued to increase until the e11d of. the 
experiment. It reached. 3 0% at 7 days after the treatment began. For the cells that were 
clanged to control nledul~n., the percentage of cells in C-~/:~I: deereased and exhibited a 
similar Dl`~A cell cycle profile as control cells at day 4 (figure 3b). The representati~re 
histograms of flow cytometry data are shown in figure 3 c. 
The expression of full length APC protein in HT29-APC cells 
To vel-ify that. full length APC expression v~Tas induced try Z11C1~ in ~:'I'~9 cells, bath 
FIT29-APC and. I-~T29m~AL cells were treated for 24 hours with or r;~itllo~~.~:t 100 µM ZnCI~ 
alad tl~e i:n.ducibl.e full. length APC protein. expression vas detected by ~veste~4n. blot analysis. 
.As shown in flgt~~•e 4, full length APC was not detected. ill an~r of the I~T29-SAL treated 
cells, which conflrined that it was an approp~-late contr. al cell line fol- this study ~2+G~ . The 
expression of full length APC wa.s detected in ZnC12 treated ~IT29 APC cells with or without 
resveratrol.. The amount of full length APC expressed after ~0 µ:lm resveratrol treatment 
(average band density 1.88E5 ~ 1.85E5 units) was not significantly different in comparison 
with vehicle control (average band density 3.43E5 ~ 0.9E5 units) (P >0.05). 
The effect of .APC on res~eratrol's impact on cell growth and cell c~Tcle 
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~ot11 I~T29-ABC and I--IT29-U~.L cells were treated with 0 to 80 µM of resveratr~~l 
for 48 hours. The :numbers o.f. cells from. each. treatment are sl~.own in figure ~. Co:~npared to 
vehicle control, the total cell number was significantly decreased. ~Tith 60 µM resveratrol in 
both HT29-A.I~C cells (1'<0.0~) and 1-IT2~-GAL cells (P<0.05). 
We also evaluated the impact of foil length A~'C expression an HT29 cells sensitivity 
to ~•csveratrol treatment. 2nC12 (l. 00 µv1) was used to induce full length Al'C exp~•ession. 
~igu.re 6 shows that the proportion of cells in G2/M was increased. frorr~ about 22% to about 
32% by 80 µM resveratrol., and to about 44% by SO µM ap~.genin. i:n~ both :l~l":1:~2~WA.1'C; a~.d 
HT2~-SAL cells when the cells were treated fog• 48 lours. A.pigenin was used as a positi~fe 
control [40]. When full-le:~~.gtl~ APC expression was induced in I~T2~-APC cells by 100 µM 
~nClz, the G 2M arrest vas abolished in apiginein-treated cells, but the expression of full 
length ABC did not alter G2M ar~•est ley resveratrol Tl~.e increase in G2M with the treatment 
of apigenin and resveratrol in HT29-GAL, cells was co~~parable to tl~e increase obtained in 
:HT29-APC cells. but in ~IT2~-GAL cells, the values did not change with or without :ZnCI~. 
~3e~le~lon of ~hc t~ .or su~~essl+~n gene X53 did nod c~r~.gc ~hc cells scn.sl~l~~l~~ ~o 
~resver~.t~~al In HST ~1+~ cells 
Human colon cancer HCT116 cells with wild type p53 (HCT116 p53+/+) and a 
parallel p53 knock out cell line (HCTI 16 p53-/-) were treated with 0 to 30 µM of resveratrol 
for 24, 48 or 72 hours. Cell number and cell cycle distribution was determined as described 
in the Methods. A significant growth inhibition was observed at 24 hours with 25 and 30 µM 
resveratrol in both of the cell lines (p<0.05, figure 7). When incubated with resveratrol for 48 
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and 72 hours, significant decreases in cell number occurred at doses of 20 µM and higher for 
both of the cell lines. The 72 hours EC50 of resveratrol 26.24.2 µM for HCT116 p53-/-
cells and 21.32.6 µM. 
Figure 8 shows the G2/M distribution at 72 hours of resveratrol treatment for each cell 
lines. A significant G2M accumulation was observed at 25 µM fog• H~;T11 ~ {pS3-/-} cells 
{f`~O.OS}. The slope of the log of the percentage of ~2M against resveratrol concentration of 
each cell line was esti~~.ated and con~pa~•ed b~T linear regression. ~o si.gnificant difference vas 
observed. between the t~vo slopes {F'>0.05}. 
I~.estor+cd MM>~. activit~r i~. ~'T11~ cells did not chant tl~c cells s~ensitivit~ to 
resvcr~.trol 
As shown in figure 9, the expression of hMLH 1 p~•otein was detected in 
1--ICT 11 C+cl~r3 cells but :not in HCT 1 l ~ cells. Both I~CT 1. 1. ~ {I~M~ deficient} and 
1--ICT 11 ~+clu•3 {MMR proficient} cells ~ve~•e treated wit110 to S 0 µM resveratrol for 4~ hours 
to evaluate wl~ethe:~• changing of M.l'vl~.. status in human colon ca:~~.cer cells would have an 
impact on their sensitivity to resveratrol. Figu~•e 10 shows the cell number of each treatment. 
The 481~.ours ECSO vas 3 :l .5~3.~8 µM for I~CT11 ~ +-cl~_r3 cells and 30.4~3.2~ µM f`o:r. 
FIC T 11 ~ cells. 
The G2/M distribution of each treatment is shown in figure 11. For HCT 116 cells, the 
percentage of cells in G2M was 6.9% for cells treated with 0µM resveratrol and 20.9% for 
5 0 µM resveratrol. For HCT 116+chr3 cells, the percentage of cells in G2M increased from 
16.6% to 37.6% after 50 µM resveratrol treatment. A significant G2M accumulation was 
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observed at 30 µM and higher concentrations for both HCT116 and HCT116+chr3 cells 
(P<0.05). No significant difference was observed between the slopes of the log of the 
percentage of G2M against resveratrol concentration of each cell line (P>0.05). 
Discussion 
Revveratrol was observed to inhibit cell growth and induce cell cycle arrest in human 
colon cancer SW480, DLD1, HCTl 16, and HT29 cells. Different sensitivity to resveratrol 
treatment was observed among these cell lines. SW480 and DLD 1 cells were more sensitive 
to resveratrol than the other two cell lines while HT29 cells were found to be the most 
resistant. Colon cancer cells with mutant or wild type tumor suppressor genes p53, APC, or 
hMLH 1 responded to resveratrol treatment very similarly. The mutant cells did not show 
increased sensitivity to resveratrol compared with cells normalized by restoration of the wild 
type gene. The result indicated that resveratrol may not selectively inhibit the growth of 
colon cancer cells with or without mutations in these genes. 
Four human colon cancer cell lines were treated with resveratrol for 48 hours and a 
significant growth inhibition was observed in each of the cell lines. The cells also showed a 
reduction in the proportion of cells in GO/G 1 and an accumulation in S and G2M in a dose 
dependent manner. The most sensitive cells were SW480 and DLD 1 cells, which have 
mutations in p53, APC, and ki-ras [41,42] . This is supported by the work of Delmas et al 
who showed that 3 0 µM resveratrol inhibited cell growth by 5 0% and induced a significant 
increase in S phase in S W480 cells after 24 hours treatment [ 13 ] . A significant G2/M arrest 
was observed in the same cells when treated with resveratrol for 72 hours. Liang et al found 
that resveratrol at 50 µM inhibited growth of HT29 cells and induced arrest in the G2/M 
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phase of the cell cycle after 48 hours treatment [11]. The differential sensitivity to resveratrol 
in various colon cancer cell lines was also observed by Delmas et al, when they treated 
SW620, HCT116, and HT29 with resveratrol. It was found that SW620 was the most 
sensitive cell line to resveratrol induced cell death and HT29 was the most resistant cell line 
[43]. 
We examined SW480 cells after resveratrol was removed to see whether the growth 
inhibition and cell cycle arrest effects of resveratrol were cytostatic or cytotoxic. Our studies 
showed that after the cells are treated with resveratrol for 48 hours, the cell number was 
decreased by 60 to 70% and the percentage of cells in G2M was increased about 60% in the 
25 µM resveratrol treated cells relative to the vehicle control group. However, 2 days after 
resveratrol was removed and replaced with fresh medium, SW480 cells resumed growth and 
exhibited similar cell cycle profiles as the control cells. The result suggested that resveratrol 
induced cell growth inhibition and cell cycle arrest is reversible, which was also observed in 
other cancer cell lines, such as THP-1 human monocytic leukemia cells [44], LNCaP prostate 
cancer cells [45], and U93 7 human monocytic cells [46] . It indicated that the inhibition of 
cell growth by resveratrol seems to be cytostatic rather than cytotoxic. 
Mutations in APC are found to occur in the early stage of tumorgenesis [20, 47] . 
f-Iuman colon. HT29 cells have truncated APC gene. volgestein's laboratory developed a 
unique model to study the function of wild type APC, in wl~ich the cells were transfected 
~v~tl~ a vector containing full length APC driven by ~~.etallotl~ia~~.ein promoter. The expresses 
of full length APC was induced by 100 µM ~nCl~~ as shown in Pigure 4. Resveratrol was 
found to have ~~.o impact on tl~.e APC expression. HT29-CJAL cells were used as a control cell. 
line, full length APC was not expressed in tl~is cell line upon treat~~ent with ZnCI~ as 
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confirmed by western blot analysis. It was found that the expression of full length APC 
clanged the cells sensitivit~~ to apigenin, which is consistent with studies by Chung et al in 
our laboratory [40]. However, no differential growth or cell cycle profile was observed in the 
cells with or without wild type APC when they were treated with resveratrol. These 
observations suggest that APC protein may not modulate resveratrol's growth inhibition 
effect. Our observation may help to explain the reason that studies in the Min mouse model 
in vivo were not conclusive regarding resveratrol's tumor prevention effect [16, 17]. 
Human colon cancer HCT116 cells have wild type p53 and the HCT 116 p53 (-/-) 
cells were constructed by homologues recombination [48]. The targeted deletion of wild type 
p53 was verified by both southern blot and western blot analysis [48]. The p53 deficient cells 
were found to be more sensitive to the apoptotic effect of adiamycin or irradiation but they 
were resistant to 5-fluorouracil compared with wild type cells [49]. Our results showed after 
72 hours of incubatrion with resveratrol, the ECSOs of these cell lines were very close to each 
other and thus there was no evidence of differential sensitivity of p53 wild type or knock out 
cells to resveratrol. The results are consistent with observations from Mahyar-Roemer et al 
that resveratrol induced apoptosis was independent of p53 in human colon cancer HCT116 
cells [50]. 
Several studies have been conducted to evaluate whether resveratrol inhibits cell 
growth and induces apoptosis though p53, however the results have not been conclusive. 
Resveratrol has been found to increase p53 activity in mouse epidermal cells [29] and induce 
serine phosphorylation of p53 in human prostate and thyroid cancer cells [30,31], however 
the activation of p53 was weak and not significant in colon cancer cells [50]. Studies showed 
that resveratrol was able to induce apoptosis in normal mouse embryo fibroblasts (p53+~+) but 
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not in p53-deficient embryo fibroblasts (p53-~-) [29], while Mahyar-Roemer et al showed that 
resveratrol induced apoptosis independent of p53 in human colon cancer HCT116 cells [50]. 
Studies in human breast cancer MCF-7 cells suggested that resveratrol induced apoptosis was 
p53 dependent since the addition of the p53 inhibitor pifithrin-a blocked resveratrol induced 
apoptosis [51]. However, resveratrol induced growth inhibition in MDA-MB-435 breast 
cancer cells and induction of apoptosis in DU145 prostate cancer cells was also observed, 
and both of the cell lines had p53 mutations [51,52]. It seems that resveratrol can inhibit cell 
growth and induce apoptosis in cancer cells through both p53 dependent and p53 
independent pathways. In the present study, deletion of wild type p53 in HCT116 cells did 
not change the impact of resveratrol on cell growth and cell cycle in these cell lines, 
suggesting that resveratrol's cell regulation effect was not dependent on p53. In addition, 
compared to HCTI 16 cells, which have wild type p53; SW480 and DLD1 were more 
sensitive and HT29 cells were more resistant to resveratrol, and all of the latter three cell 
lines have p53 mutations. This result again suggested that resveratrol may inhibit cell growth 
and induce cell cycle arrest through pathways independent of p53. 
HCT116 cells are known to be MMR deficient [39]. Studies by Boland's lab showed 
that transfecting chromosome 3 into MMR deficient HCT116 cells was able to restore MMR 
function [39]. Restoration of MMR in MMR deficient HCT116 human colon cancer cells 
made the cells more sensitive to DNA damaging agents, such as MNNG 
(N-methyl-N'-nitro-N-nitrosoguanidine) [39,53]. Studies in HCT116 (MMR deficient) and 
HCT116-chr3 (MMR sufficient) cells showed that the 48 hours ECSOs of the two cell lines to 
resveratrol treatment was very similar. It suggested that the MMR repair gene hMLH 1 did 
not have an impact on the sensitivity of colon cancer cells to resveratrol treatment. A defect 
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in this model is that there are numerous genes on chromosome 3, which have also been 
transfected into the cells; therefore, HCTI 16 cells may not be an optimal control for the 
study. However, since differential sensitivity to resveratrol's growth arrest was not observed, 
the HCT 116 cells were adequate to show that addition of the hMLH 1 gene did not increase 
sensitivity to resveratrol. 
The bioavailability of resveratrol has been studies in isolated rat intestine, rodents and 
healthy human subjects [54-63 ] . The results showed that resveratrol was well absorbed and 
can be metabolized into resveratrol glucuronide or sulfate in the liver or intestinal epithelial 
cells [61-63 ] . So far, the pathways for resveratrol absorption, transport, metabolism and 
excretion have not been adequately studied. No studies have been conducted to determine the 
amount of resveratrol in specific tissues in animals or humans after prolonged dietary intake 
of resveratrol. Therefore, the physiologically relevant level of resveratrol in human colon in 
vivo can not be estimated at the present time. In the future, it will be important to determine 
if the effective concentrations found in vitro can be reached in vivo. 
In conclusion, our studies showed that reveratrol was able to inhibit colon cancer cell 
growth and induce cycle cell arrest. The growth inhibition and cell cycle arrest effect was 
reversible and not changed by the expression of tumor suppressor full length APC in HT29 
cells, depletion of p53, or restoration of MMR status in HCT 116 cells. It seems that the 
effects of resveratrol on cell growth and cell cycle may be though multiple targets and 
multiple pathways. In order to better understand whether resveratrol is able to selectively 
inhibit the growth of cancer cells, it will be important and essential to compare the impact of 
resveratrol on normal cells as well as cancer cells in the future. 
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Figure and Legend 
Figure 1 Impact of resveratrol on the growth of (a) SW480, (b) DLD1, (c) HCT116 and 
(d) HT29 cells treated for 48 hours. Each value represents mean + SE. For SW480 cells, 
the average was obtained from 9-18 replicates. For DLD1, HCT116 and HT29 cells, the 
average was obtained from 3-4 individual experiments performed in duplicate. Different 
letters indicate a significant difference of cell number within each cell line, a>b>c, P<0.05. 
Values that share two letters are not significantly different from values with either letter. 
Figure 2 Impact of resveratrol on the cell cycle distribution of SW480 (a), DLD1 (b), 
HCT116 (c) and HT29 (d) treated for 48 hours. Solid circles with solid line: percentages 
of GOl phase cells; open circles, percentages of S phase cells; solid circles with dotted line: 
percentages of G2M phase cells. The symbols represent mean ~ SE. For SW480 cells, the 
average was obtained from 9-18 replicates. For DLD 1, HCT 116 and HT29 cells, the average 
was obtained from 3 -4 individual experiments performed in duplicates. Different letters 
indicate a significant difference of cell number within each cell line, a>b>c>d, k<l<m, 
f<g<h<i, p<0.05. Values that share two letters are not significantly different from values with 
either letter. Error bars are smaller than the symbol where they can not be seen. 
Figure 3 Reversibility of resveratrol growth inhibition (a) and cell cycle effect (b) (c). 
SW480 cells were treated with vehicle control or 25 µM resveratrol for 2 days. The arrow 
indicates when part of the plates of resveratrol treated cells were washed twice with fresh 
medium and incubated with vehicle control medium. The other resveratrol treated cells and 
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control cells were retreated with resveratrol or vehicle control, respectively, in fresh medium. 
open circle: control; solid circle: 25 µM resveratrol; open triangle: cells that are treated with 
25 µM resveratrol for 2 days and then changed to 0µM resveratrol. The symbols represent 
mean ~ SE from three to five individual experiments with duplicate observations. The arrow 
indicates the change to 0µM resveratrol. Cell growth rate was estimated as the slope of the 
log of cell number against time. Studies showed that the growth rate of treated cells after 
resveratrol was removed (open triangle) was not significantly different from the control 
group (open circle) (p>0.1), while the growth rates of both the above two groups are 
significantly different from the resveratrol treated cells (solid circle) (P<0.0001). (a) showed 
the reversibility of growth inhibition by resveratrol. The cell numbers after a log 
transformation were shown on the right upper corner. The straight line showed a linear 
relationship of cell number after log transforamtion with time within each group. 
~'~.gure 3(b) showed tl~e ~-eversi.bllty of C~2I~ effect of resverat:~-ol. l~i..f..feren.t letters indicate a 
significant difference of ~2M proportion, a>b>c, p<0.0~ . Figure ~ (c) showed tl~e 
rcpresentat~vc l~~stogram data from flow Cyto~-nets y. 
Figure 3(c) showed histograms of cellular DNA content obtained by flow cytometry in 
resveratrol treated cells. *: cells were treated with 25 µM resveratrol for two days and then 
changed to 0µM resveratrol. 
Fi~ur~e ~ ~~~resslon o~ f~ll~ler~gth A~''C pratcin indc~e~ ~y ~n~12 ~r~ cells t~+~~.tc~ ~~tl~ 
resve~i~.t~;ol. HT-~9~ GAL, cells and. ITT-2~ Al'C cells were treated with 0.2°~° DMSO {vehicle 
control) or 80 µM resveratrol combined with or without 100 µIQ ~nCl7 for 24 hours. T`he 
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westenl blot analysis was performed as described in Methods. The following sho~Ts a 
representative blot from.. three individual experira~.ents. whole cell. lysate f~•on~ hu~~.an colon. 
cancer HCT 11 ~ cells was used as a positive control (PC, lane 1) [23] . Lane 2: HT29-CTRL 
cells with 0.2% DM:SO vehicle control. Lane ~ : f-IT29-GAL cells with 100 µM ZnCI~ and 
vehicle control. Lane 4: HT29-APC cells with vehicle control. Lane 5: l-IT29-APC cells with 
1.00 µM ZnCI~ and vel~.icle control. Lane ~: I-IT29-G.AL cells with 0 µM resveratrol. La~~.e ~: 
HT29-GAL cells with 100 µM ZnCI~ and 80 µM resveratrol. Lane ~: HT29-AP'C cells with 
SO µM resveratrol. Lane 9: HT29-APC cells with 100 µ:M ZnCI~ and 80 µM ~•esveratrol. 
Figure 5 Impact of resveratrol on the growth of HT29-GAL and HT29-APC cells 
treated for 48 hours. Each value represents the mean + SE. The average was obtained from 
3 -4 individual experiments with duplicate observations. Data from HT29-GAL and 
HT29-APC cells were analyzed separately. Different letters indicate a significant difference 
of cell number within each cell line, a>b>c, e>f>g, P<0.05. 
Figure 6 The impact of resveratrol on G2/M arrest of HT29-APC and HT29-GAL cells 
with the induction of ZnCl2. HT-29 GAL cells and HT-29 APC cells were treated with 
0.2% DMSO (vehicle control), 80 µM resveratrol (RES) or 80 µM apigenin (API) combined 
with or without 100 µM ZnCl2 (Zn) for 24 hours. Values represent the mean+SE, The 
average was obtained from 3-5 individual experiments with duplicate observations. Data 
from HT29-GAL and HT29-APC cells were analyzed separately. For HT29-GAL cells, 
a<b<c, P<0.05. For HT29-APC cells, d<e<f, P<0.05. 
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Figure 7 Impact of resveratrol on the growth of HCT116 p53-/- and HCT116 p53+/+ 
cells treated for 24, 48, 72 hours. Values represent mean+SE, N=3-5. Data from HCT116 
p53-/- and HCTI 16 +/+ were analyzed separately. Different letters indicate a significant 
difference of cell number within each cell line a>b, h>i, c>d, e>f, p>q>r, P<0.05. 
Figure 8 Effect of resveratrol on G2M accumulation of HCT 116 p53-/- and HCT 116 
p53+/+ cells treated 72 hours. Values represent mean+SE, N=3 -5 . Data from HCT 116 
p53-/- and HCT116 +/+ were analyzed separately. Different letters indicate a significant 
difference within each cell line, a<b, c<d, p<0.05. The pertage of G2M after a log 
transformation were shown on the right upper corner. Open cirle : HCT 116 p5 3 -/-; solid 
square: HCTI 16 p53+/+. The straight line showed a linear relationship of G2M after log 
transforamtion with resveratrol concentration within each cell line. 
Figure 9 Expression of hMLHl in HCT116 and HCT116+chr3 cells. Whole cell lysate 
from human colon cancer SW480 cells was used as a positive control [64](PC, lane 1). Lane 
2 is HCTI 16+chr3 and lane 3 is HCT116. 
Figure 10 Impact of resveratrol on the growth of HCT116 +chr3 and HCT116 cells 
treated for 48 hours. Values represent mean+SE, N=3 -5 . Data from HCT 116+chr3 and 
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HCT 116 were analyzed separately. Different letters indicate a significant difference of cell 
number within each cell line a>b, c>d>e, P<0.05. 
Figure 11 Effect of resveratrol on G2M accumulation of HCT116+chr3 and HCT116 
cells treated for 4~ hours. Values represent mean+SE, N=3 -5 . Data from HCT 116 and 
HCT 116+chr3 were analyzed separately. Different letters indicate a significant difference 
within each cell line. a<b, c<d<e, p<0.05. The pertage of G2M after a log transformation 
were shown on the right upper corner. Open cirle: HCT116 p53-/-; solid square: HCTl 16 
p53+/+. The straight line showed a linear relationship of G2M after log transforamtion with 
resveratrol concentration within each cell line. 
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CHAPTER 3. GENERAL CONCLUSIONS 
The current study examined the effect of resveratrol on cell growth and cell cycle in 
four human colon cancer cell lines, SW480, DLD 1, HCT 116 and HT29. The study also 
investigated the impact of tumor suppressor gene APC, p53 and hMLHl on the growth 
inhibitory and cell cycle arrest effect of resveratrol in human colon cancer cells. We 
hypothesized that restoration of full length APC in HT29 cells and hMLH 1 in HCT 116 cells 
will make the cells more resistant to resveratrol, and that knock out of wild type p53 in 
HCT 116 cells will sensitize these cells to resveratrol. 
In order to test our hypothesis that restoration of wild type APC in colon cancer cells 
will make them more resistant to resveratrol, we used a cell model developed in Bert 
Volgestein's lab, in which HT29 cells, which have truncated APC gene, were transfected 
with a vector containing ft.~ll length APC driven by rnetallothionein promoter (~/Iorin, 1996). 
The cont~~ol cell line ~va.s HT29-C~.AL cells, in which a ~-galactosidase gene was transfected 
into the cells. We did not observe any significant difference in the cell cycle profile between 
the cells which have wild type or mutant APC when they were treated with resveratrol. In 
this study, apigenin was used as a positive control. Consistent with what Chung et al 
(unpublished) have found previously, our results showed that the expression of full length 
APC in HT29 cells blocked apigenin induced C~21~ a~-~•est in the cell cycle. overall, it seemed 
tl~.at the cell cycle arrest effect of resveratrol was not n~.odulated by tun~.or suppressor gene 
APC. 
We ~1so tested tl~e hypotheses that targeted deletion of wild type p~3 gene will r~~.ake 
the cells more sensitive to resve~Aatrol. Our results showed that at 72 hours the EC50 of 
resveratrol, the effective concentration at which 50% of growth inhibition was observed, was 
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very similar for HCTl 16 p53+/+ cells and HCTl 16 p53-/- cells. These results implied that 
the resveratrol induced growth inhibitory effect was not p53 dependent. This result was 
consistent with observations of Mahyar-Roemer et al showing that resveratrol induced 
apoptosis was p53 independent in HCT 116 cells (Mahyar-Roemer, et al., 2001). It was found 
that resveratrol induced apoptosis was p53 dependent in mouse embryo cells, breast cancer 
MCF-7 cells and human liver cancer cells (Huang et al., 1999; Kuo et al., 2002). Therefore, 
resveratrol induced growth arrest in cancer cells seems be through both p53 dependent and 
p53 independent pathways, depending on the specific cell type. 
Researchers in Boland's laboratory constructed a cell line MMR-chr3 by transfecting 
chromosome 3 into MMR deficient HCT 116 cells to restore MMR function (Hawn et al., 
1995). We treated HCT 116 (MMR deficient) and HCT 116-chr3 (MMR sufficient) cells with 
resveratrol and found that the growth inhibitory and cell cycle affect of resveratrol on the two 
cell lines was very similar, which suggested that the MMR system did not have an impact on 
the sensitivity of colon cancer cells to resveratrol treatment. 
Overall, our results showed that growth inhibition and cell cycle arrest effect of 
resveratrol in human colon cells was not changed by the expression of tumor suppressor full 
length APC, depletion of p53, or restoration of MMR status. The results provided valuable 
information and some foundation for future investigation of resveratrol as a cancer 
prevention agent. There are several potential future directions this research should explore in 
the future, such as comparing the growth inhibition and cell cycle arrest effect of resveratrol 
in tumor cells with or without mutant Ki-ras, determining whether resveratrol induces cell 
death in normal colon cells as well as tumor cells. 
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In addition to arresting cells in S and G2M phase of the cell cycle, resveratrol was 
also found to be able to induce apoptosis in colon cancer cells. Studies showed that 
resveratrol induced apoptosis in HCT 116 cells was though a mitochondria dependent 
pathway (Mahyar-Roemer et al., 2001). Resveratrol was found to induce apoptosis in SW480 
cells through the death receptor pathway. Treatment of SW480 cells with resveratrol induced 
the clustering of death receptor, Fas, redistribution of Fas, FADD (Fas-associating protein 
with death domain) and procaspase-8, and formation of DISC (death-inducing signaling 
complex) (Delmas et al., 2003). Induction of capase-3 activity by resveratrol was also 
observed in Caco-2 cells (Wolter et al., 2001), and HT29 cells in our laboratory (results not 
included in this thesis). Both APC and MMR were found to mediate the process of apoptosis. 
Restoration of wild type APC in cancer cells with APC mutation induced apoptosis in these 
cells (Morin et al., 1996). MMR deficient tumor cells were found to be less sensitive to DNA 
damaging agent induced apoptosis than MMR proficient cells (Fedier et al., 2004). For future 
studies, it will be interesting to know whether the APC gene and MMR systems are involved 
in resveratrol induced apoptosis. 
Ras, an oncogene, which is important in tumor development, has been found in 
30-50% of colon cancers (Bos et al., 1987). Activated Ras tends to promote tumor growth by 
inducing cell proliferation and interfering with apoptosis (Cox and Der, 2003). As discussed 
in the chapter one literature review, AOM treated rodents that have frequent Ki-ras mutation 
in ACF appeared to be more sensitive to resvertrol than APC min mice, which have APC 
mutations. In the four cell lines studied in the current thesis, HT29 cells, which have wild 
type Ki-ras, were more resistant to resveratrol than the other three cell lines SW480, HCT116 
and DLD1, which have mutated Ki-ras. Therefore, it is reasonable and valuable to compare 
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the effect of resveratrol in tumor cells with or without mutant Ki-ras. The results may be 
helpful to explain the differential sensitivity to resveratrol between the above two animal 
models. 
In the current study, we observed that HT29 cells were more resistant to resveratrol 
induced growth inhibition. and cell cycle arrest than the other three cell lines. Cummings et al 
found that HT29 cells had a much higher protein level of UDP-glucuronosyltransferases 
(UGT), a phase II detoxification enzyme, and glucuronidase activity than other colon cancer 
cell lines such as SW480 and HCTl 16 (Cummings et al., 2003). The author also found that 
glucuronidation of the cancer therapeutic agent SN-38 by UGT changed the drug to be a 
substrate of drug transport proteins MRP and P-glycoprotein, which enhanced the removal of 
the drug from the cell, and this process may account for higher resistance of tumor cells to 
the same drug. Resveratrol was found to be metabolized intro resveratrol glucuranide and 
resveratrol sulfate shortly after its uptake by human colon cancer Caco-2 cells (Kaldas et al., 
2003). The results of our study showed that HT29 cells were more resistant to resveratrol 
induced growth inhibition effect than SW480 and HCT116 cells. Future studies on the 
relationships of human colon cancer cells sensitivities to resveratrol, their gluconidase and 
sulfate activity and the intracellular concentration of resveratrol might be helpful to explain 
our observations and also provide more information on resveratrol as a cancer prevention 
agent. 
It should be noted that tumor cells usually have multiple genes mutated and 
malfunctioning at the same time. In our study, we only normalized the cells with respect to a 
single tumor suppressor gene. In the future, it may worthwhile to normalize two or more 
genes in a given colon cancer cell model to study the effect of resveratrol, as we know now 
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that the growth inhibitory effect of resveratrol may though multiple targets in the cells. 
It is expected that an efficient cancer prevention agent would selectively kill tumor cells at 
Lower concentrations than normal cells. In our study, we only compared the effect of 
resveratrol on tumor cells with or without tumor suppressor genes. For further studies, we 
should treat human colon cancer cells as well as normal cells. Because the proliferation rate 
of normal cells are very slow, we can hardly compare the growth inhibitory effect of 
resveratrol on normal cells and concern cells. However, it is still valuable to compare 
whether resveratrol induce cell death in a similar manner in normal cells and cancer cells.The 
comparision will help to elucidate the mechanism of resveratrol in cancer prevention. In 
addition, the toxicology studies of resveratrol may provide guidelines for the using of 
resveratrol as a dietary supplement. 
In conclusion, our studies showed that reveratrol inhibited colon cancer cell growth 
and induced cycle cell arrest in a reversible manner. The expression of tumor suppressor full 
length APC in HT29 cells, depletion of p53, or restoration of MMR status in HCT 116 cells 
did not change colon cancer sensitivity to resveratrol. The evidence suggests that resveratrol 
may inhibit cell growth and induces cell cycle arrest through multiple targets and pathways. 
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